GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.28+0.04 (+1.79%)
Close on Nov 19, 2026Market cap $103.16MP/E –Yield –
Genelux shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Genelux's shares outstanding was 45M at Jun 30, 2026. For fiscal 2025 it was 37M, up 18.2% from the year before.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 37M | +18.2% |
| FY2024 | Dec 31, 2024 | 31M | +28.7% |
| FY2023 | Dec 31, 2023 | 24M | +168.0% |
| FY2022 | Dec 31, 2022 | 9M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 45M | +18.5% |
| Q1 FY2026 | Mar 31, 2026 | 44M | +26.4% |
| Q4 FY2025 | Dec 31, 2025 | 38M | +10.2% |
| Q3 FY2025 | Sep 30, 2025 | 38M | +9.7% |
| Q2 FY2025 | Jun 30, 2025 | 38M | +27.8% |
| Q1 FY2025 | Mar 31, 2025 | 35M | +30.1% |
| Q4 FY2024 | Dec 31, 2024 | 35M | +29.1% |
| Q3 FY2024 | Sep 30, 2024 | 35M | +31.8% |
| Q2 FY2024 | Jun 30, 2024 | 30M | +18.4% |
| Q1 FY2024 | Mar 31, 2024 | 27M | +37.2% |
| Q4 FY2023 | Dec 31, 2023 | 27M | +193.6% |
| Q3 FY2023 | Sep 30, 2023 | 26M | +160.2% |
| Q2 FY2023 | Jun 30, 2023 | 25M | +175.1% |
| Q1 FY2023 | Mar 31, 2023 | 20M | +114.9% |
| Q4 FY2022 | Dec 31, 2022 | 9M | – |
| Q3 FY2022 | Sep 30, 2022 | 10M | – |
| Q2 FY2022 | Jun 30, 2022 | 9M | – |
| Q1 FY2022 | Mar 31, 2022 | 9M | – |
See a number that looks wrong?